TY - JOUR
T1 - Radiological evaluation of response to treatment
T2 - Application to metastatic renal cancers receivinganti-angiogenic treatment
AU - Ammari, S.
AU - Thiam, R.
AU - Cuenod, C. A.
AU - Oudard, S.
AU - Hernigou, A.
AU - Grataloup, C.
AU - Siauve, N.
AU - Medioni, J.
AU - Fournier, L. S.
PY - 2014/1/1
Y1 - 2014/1/1
N2 - Targeted therapies have considerably improved the prognosis of patients withmetastatic renal cancer (mRCC) but there are no reliable response assessment criteria reflectingthe clinical benefits, because there is no regression in size, or it is delayed. Such criteria wouldhelp early identification of non-responders, who would then benefit from a change of treatment,and would avoid their being subjected to unnecessary side effects related to the treatment. Wewill review the imaging techniques currently available for evaluating tumour response in mRCCpatients, including the response evaluation criteria in solid tumours (RECIST), the Choi criteria,the modified Choi criteria, and the CT size and attenuation criteria (SACT). We will also dis-cuss functional imaging techniques, which are based on the physiological characteristics of thetumours, such as perfusion CT, magnetic resonance imaging or ultrasound (DCE-CT, DCE-MRI,DCE-US), diffusion MRI, BOLD MRI and new positron emission tomography (PET) tracers. It isnot possible at present to propose a unanimously acknowledged criterion for evaluating tumourresponse to targeted therapy. However, there is a real need for this according to oncologists andthe pharmaceutical industry, and radiologists need to be involved in reflecting on the subject.
AB - Targeted therapies have considerably improved the prognosis of patients withmetastatic renal cancer (mRCC) but there are no reliable response assessment criteria reflectingthe clinical benefits, because there is no regression in size, or it is delayed. Such criteria wouldhelp early identification of non-responders, who would then benefit from a change of treatment,and would avoid their being subjected to unnecessary side effects related to the treatment. Wewill review the imaging techniques currently available for evaluating tumour response in mRCCpatients, including the response evaluation criteria in solid tumours (RECIST), the Choi criteria,the modified Choi criteria, and the CT size and attenuation criteria (SACT). We will also dis-cuss functional imaging techniques, which are based on the physiological characteristics of thetumours, such as perfusion CT, magnetic resonance imaging or ultrasound (DCE-CT, DCE-MRI,DCE-US), diffusion MRI, BOLD MRI and new positron emission tomography (PET) tracers. It isnot possible at present to propose a unanimously acknowledged criterion for evaluating tumourresponse to targeted therapy. However, there is a real need for this according to oncologists andthe pharmaceutical industry, and radiologists need to be involved in reflecting on the subject.
KW - Anti-angiogenic
KW - Functional imaging
KW - Metastatic renalcancer
KW - RECIST
KW - Tumour response
UR - http://www.scopus.com/inward/record.url?scp=84903820145&partnerID=8YFLogxK
U2 - 10.1016/j.diii.2013.01.019
DO - 10.1016/j.diii.2013.01.019
M3 - Short survey
C2 - 24906810
AN - SCOPUS:84903820145
SN - 2211-5684
VL - 95
SP - 527
EP - 539
JO - Diagnostic and Interventional Imaging
JF - Diagnostic and Interventional Imaging
IS - 6
ER -